News
2024
February 15, 2024. T-CURX participates at the 6th European CAR-T congress in Valencia, Spain
Read moreFebruary 9, 2024. T-CURX extends its management team with Marion Jung, PhD, as its new Chief Operating Officer
Read moreJanuary 16, 2024. T-CURX will present at Advanced Therapies Week in Miami-Beach, FL
Read more2023
November 14, 2023. T-CURX attends PEGS-Europe conference
Read moreNovember 6, 2023. T-CURX to attend BIO-Europe conference
Read moreAugust 28, 2023. T-CURX GmbH announces appointment of two industry leaders to its Board of Directors
Read moreJune 6, 2023. T-CURX GmbH announces senior leadership appointments to significantly bolster clinical team
Read moreMay 15-16, 2023. T-CURX to participate at 2023 Bio€quity conference in Dublin, Ireland
Read moreMay 3-4, 2023. T-CURX to attend and to present at LSX World Congress in London
Read moreFeb 9-11, 2023. T-CURX co-founder Prof. M. Hudecek is co-chairing the 5th European CAR-T congress of EHA in Rotterdam, The Netherlands
Read more2022
December 15, 2022. Tom Loeser appointed as CFO of T-CURX & T-CURX attending the 41st JPM Annual Healthcare Conference 2023
Read moreOctober 6, 2022. Ulf Grawunder, PhD, experienced Biotech Executive becomes new CEO of T-CURX
Read moreSeptember 15, 2022. Caroline Burger, PhD, appointed as T-CURX' Global Head Business Development
Read moreJuly 12, 2022. Successful completion of non-clinical tissue cross reactivity study for the binder of T-CURX CAR-T cell pipeline product for AML patients
Read more2021
September 19, 2021. € 11.6 Mio BMBF funded project IMAGINE awarded to a consortium of seven German collaboration partners, including T-CURX
Read moreMarch 18, 2021. T-CURX completes successful scientific advice meeting with Geman Paul-Ehrlich-Institute for T-CURX CAR-T cell program in Acute Myeloid Leukemia
Read moreMarch 1, 2021. T-CURX is a partner in the competitive BMBF-funded "Clusters4Future" Project SaxoCell
Read more2020
December 15, 2020. € 9.5 Mio EU Innovative Medicines Initiative (IMI) grant "T2EVOLVE" awarded to an international consortium of 27 partners, including T-CURX
Read moreSeptember 9, 2020. T-CURX obtains exclusive license from the University of Würzburg, Germany, for a portfolio of 8 patent families, covering novel CAR-T cell technologies and products
Read moreJune 22, 2020. Start of First-in-Human (FiH) clinical trial with SLAM-F7/CS1 specific CAR-T cells using T-CURX transposon technology
Read more2019
November 15, 2019. € 11 Mio EU Innovative Medicines Initiative (IMI) grant "imSAVAR" awarded to 26 partners, including T-CURX
Read more2018
January 2, 2018. € 6.1 Mio Horizon 2020 grant awarded to the CARAMBA Consortium, including T-CURX as SME partner
Read more2017